Table 1 Characteristics of patients with T2-T4 esophageal SCC.
From: Survival benefit of surgery to patients with esophageal squamous cell carcinoma
Patients Treatment | |||
|---|---|---|---|
Definite CCRT | Surgery+/− Neo/adjuvant Tx | Palliative treatment | |
Number (%) | 577 (100%) | 380 (100%) | 273 (100%) |
Age | |||
<50y/o | 168 (29.1%) | 119 (31.3%) | 62 (22.7%) |
50–64y/o | 268 (46.4%) | 205 (53.9%) | 111 (40.7%) |
>64y/o | 141 (24.4%) | 56 (14.7%) | 100 (36.6%) |
Gender | |||
Female | 35 (6.1%) | 16 (4.2%) | 27 (9.9%) |
Male | 542 (93.9%) | 364 (95.8%) | 246 (90.1%) |
Clinical T stage | |||
T2 | 48 (8.3%) | 76 (20.0%) | 30 (11.0%) |
T3 | 254 (44.0%) | 214 (56.3%) | 114 (41.8%) |
T4 | 275 (47.7%) | 90 (23.7%) | 129 (47.3%) |
Clinical N stage | |||
N0 | 31 (5.4%) | 72 (18.9%) | 41 (15.0%) |
N1 | 205 (35.5%) | 150 (39.5%) | 169 (61.9%) |
N2 | 217 (37.6%) | 114 (30.0%) | 43 (15.8%) |
N3 | 124 (21.5%) | 44 (11.6%) | 20 (7.3%) |
